^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AR expression

    i
    Other names: AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
    Entrez ID:
    367
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (NCI-2018-01054) (NCT03360721)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/06/2018
    Primary completion :
    04/30/2027
    Completion :
    04/30/2027
    PTEN
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)
    Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC (NCT06222593)
    Phase 1/2
    State University of New York at Buffalo
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/01/2024
    Primary completion :
    07/01/2026
    Completion :
    07/01/2027
    AR • KLK2
    |
    AR expression • KLK2 expression
    |
    sunitinib • bicalutamide
    Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (NCT02676986)
    Phase 2
    Queen Mary University of London
    Completed
    Last update posted :
    07/04/2024
    Initiation :
    08/10/2015
    Primary completion :
    12/31/2016
    Completion :
    12/31/2016
    HER-2 • ER • AR
    |
    AR positive • AR expression
    |
    enzalutamide • exemestane
    Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer (NCT02750358)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/21/2024
    Initiation :
    05/19/2016
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    HER-2
    |
    AR expression
    |
    enzalutamide
    Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer (NCT02955394)
    Phase 2
    University of Colorado, Denver
    Active, not recruiting
    Last update posted :
    06/10/2024
    Initiation :
    09/21/2017
    Primary completion :
    02/17/2023
    Completion :
    02/01/2027
    HER-2 • ER
    |
    AR expression
    |
    enzalutamide • fulvestrant
    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer (NCT04573231)
    Phase 2
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    05/22/2024
    Initiation :
    05/24/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2 • FOLH1
    |
    HER-2 negative • AR expression • FOLH1 expression
    Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer (NCT02007512)
    Phase 2
    Pfizer
    Active, not recruiting
    Last update posted :
    04/26/2024
    Initiation :
    12/13/2013
    Primary completion :
    09/23/2016
    Completion :
    06/28/2024
    HER-2 • AR
    |
    AR expression
    |
    enzalutamide • exemestane
    Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer (ENPAC) (NCT02684227)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    10/16/2023
    Initiation :
    08/24/2016
    Primary completion :
    09/27/2023
    Completion :
    09/27/2023
    AR
    |
    AR expression
    |
    carboplatin • paclitaxel • enzalutamide
    A Study of CC-90011 and Comparators in Participants With Prostate Cancer (NCT04628988)
    Phase 1
    Celgene
    Completed
    Last update posted :
    09/13/2023
    Initiation :
    07/28/2021
    Primary completion :
    05/26/2023
    Completion :
    05/26/2023
    AR
    |
    AR expression
    |
    enzalutamide • abiraterone acetate • prednisone • pulrodemstat (CC-90011)
    Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) (NCT02605486)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/30/2023
    Initiation :
    11/11/2015
    Primary completion :
    11/01/2024
    Completion :
    11/01/2024
    HER-2 • AR
    |
    AR expression
    |
    Ibrance (palbociclib) • bicalutamide
    Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies (NCT01974765)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    04/28/2023
    Initiation :
    11/05/2013
    Primary completion :
    02/28/2022
    Completion :
    02/28/2022
    AR
    |
    AR expression
    |
    enzalutamide
    Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer (NCT03123978)
    Phase 1
    Mamta Parikh
    Completed
    Last update posted :
    04/26/2023
    Initiation :
    01/09/2017
    Primary completion :
    01/14/2022
    Completion :
    04/19/2022
    AR
    |
    AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression
    |
    enzalutamide • niclosamide